MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer

Cancer Letters

Volumn 362, Issue 2, 2015, Pages 208-217

  Chen, Di ^a   Guo, Weijie ^a,b   Qiu, Zhaoping ^a   Wang, Qifeng ^b   Li, Yan ^b   Liang, Linhui ^b   Liu, Li ^b   Huang, Shenglin ^b   Zhao, Yingjun ^b   He, Xianghuo ^a,b  

^a SHANGHAI CANCER INSTITUTE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

CCNE2; MiR 30d; Motility; Non small cell lung cancer; Proliferation

Indexed keywords

CELL ANTIGEN; CYCLIN E2; MICRORNA; MICRORNA 30D 5P; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CCNE2 PROTEIN, HUMAN; CYCLINE; MIRN30 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CARCINOGENESIS; CELL GROWTH; CELL MOTION; DOWN REGULATION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CYCLINS; DOWN-REGULATION; HEK293 CELLS; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS;

EID: 84928207638     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.041     Document Type: Article

References (27)

1. He J., et al. Chinese Cancer Registry Annual Report 2012 2012, National Cancer Center & Disease Prevention and Control Bureau.
2. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90. 10.3322/caac.20107.
3. Verdecchia A., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007, 8:784-796. 10.1016/S1470-2045(07)70246-2.
4. Joshi P., Middleton J., Jeon Y.J., Garofalo M. MicroRNAs in lung cancer. World J. Methodol 2014, 4:59-72. 10.5662/wjm.v4.i2.59.
5. Kumar M.S., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3903-3908. 10.1073/pnas.0712321105.
6. Kasinski A.L., Slack F.J. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012, 72:5576-5587. 10.1158/0008-5472.CAN-12-2001.
7. Jusufovic E., et al. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS ONE 2012, 7. e45577. 10.1371/journal.pone.0045577.
8. Chen Z., et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J. Exp. Clin. Cancer Res 2010, 29:151. 10.1186/1756-9966-29-151.
9. Hurteau G.J., Carlson J.A., Spivack S.D., Brock G.J. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007, 67:7972-7976. 10.1158/0008-5472.CAN-07-1058.
10. Yang Y., et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J. Clin. Invest 2011, 121:1373-1385. 10.1172/JCI42579.
11. Hatley M.E., et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010, 18:282-293. 10.1016/j.ccr.2010.08.013.
12. Liu X., et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest 2010, 120:1298-1309. 10.1172/JCI39566.
13. Garofalo M., et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509. 10.1016/j.ccr.2009.10.014.
14. Yao J., et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010, 51:846-856. 10.1002/hep.23443.
15. Yang Y., et al. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet. Cytogenet 2010, 200:127-133. 10.1016/j.cancergencyto.2010.03.014.
16. Markou A., Sourvinou I., Vorkas P.A., Yousef G.M., Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 2013, 81:388-396. 10.1016/j.lungcan.2013.05.007.
17. Zhang P., et al. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J. Pathol 2014, 232:308-318. 10.1002/path.4294.
18. Wu C., et al. MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma. Cell. Signal 2013, 25:1212-1221. 10.1016/j.cellsig.2013.01.028.
19. Lu Y., et al. Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS ONE 2009, 4. e6159. 10.1371/journal.pone.0006159.
20. Kobayashi N., et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012, 3:1455-1471.
21. Esposito F., et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J. Clin. Endocrinol. Metab 2012, 97:E710-E718. 10.1210/jc.2011-3068.
22. Hwang H.C., Clurman B.E. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005, 24:2776-2786. 10.1038/sj.onc.1208613.
23. Theodorou V., et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat. Genet 2007, 39:759-769. 10.1038/ng2034.
24. Caldon C.E., Musgrove E.A. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 2010, 5:2. 10.1186/1747-1028-5-2.
25. Caldon C.E., et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol. Cancer Ther 2012, 11:1488-1499. 10.1158/1535-7163.MCT-11-0963.
26. Zhang Q., et al. miR-375 and miR-30d in the effect of chromium-containing Chinese medicine moderating glucose metabolism. J. Diabetes Res 2014, 2014. 862473. 10.1155/2014/862473.
27. Hollern D.P., Honeysett J., Cardiff R.D., Andrechek E.R. The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol. Cell. Biol 2014, 34:3229-3243. 10.1128/MCB.00737-14.